Result: $87.4 million settlement
The Synthroid Marketing Controversy
Knoll Pharmaceutical manufactures Synthroid, a brand of synthetic thyroid hormone (levothyroxine) taken by millions of Americans afflicted with hypothyroidism and other diseases of the thyroid. Knoll’s predecessor, Boots Laboratories, sponsored a university study to determine whether Synthroid and a number of less expensive thyroid hormone products were “bioequivalent.” The authors of the study concluded that Levoxyl and two generic thyroid hormone products were bioequivalent to Synthroid, and could therefore be substituted for Synthroid at substantial cost savings. Knoll denied the authors permission to publish the study.
In April 1996, the first of many class action lawsuits were filed against Knoll, alleging that Knoll wrongfully suppressed the publication of the study in order to protect Synthroid’s market share and to maintain artificially high prices for Synthroid. The lawsuits did not allege that Synthroid was unsafe or ineffective in treating thyroid disorders. The lawsuit filed by Lieff Cabraser was widely reported in the press, and received international attention.
Beginning in August 1997, the cases pending against Knoll in federal courts around the country were transferred to the Hon. Elaine E. Bucklo, a United States District Judge in Chicago, Illinois. Judge Bucklo appointed Lieff Cabraser and four other firms as Lead Counsel for the class.
In August 2000, Judge Bucklo gave final approval to a new $87.4 million settlement with Knoll and its parent company, BASF Corporation, on behalf of a class of all consumers who purchased Synthroid at any time from January 1, 1990 until October 21, 1999.
The deadline for submitting claims passed on March 10, 2000. Several appeals were taken from Judge Bucklo’s order approving the settlement.
Conclusion of the Case
After a series of appeals, the settlement proceeds were distributed in the Fall of 2003.
Civil Litigation News
Lieff Cabraser Announces Historic $235M Comprehensive Settlement with Altria in National JUUL Youth E-Cigarette Predatory Advertising, Addiction and Injury Cases
Unprecedented in scope, speed, and significance, the global settlement, reached just after plaintiffs concluded their case in the bellwether trial in San
Avery Halfon Named to Law360’s 2023 Consumer Protection Editorial Advisory Board
Law360 has selected Lieff Cabraser attorney Avery Halfon to serve as one of the lawyers on its 2023 Consumer Protection Editorial Advisory board.
Ex-JUUL COO Claims He Was Fired For Sharing Concerns About JUUL Targeting Teen Users
As reported by Law360 in its ongoing coverage of the JUUL multidistrict injury and predatory/fraudulent advertising litigation against Altria (formerly Philip Morris), extraordinary